Key result
The rabbit aorta generates ET-1(1-31) from exogenous BigET-1 via a chymase-like enzyme when ECE and NEP are inhibited, with NEP being the predominant pathway for its cleavage to a bioactive metabolite.
This preclinical study elucidates the enzymatic pathways, specifically involving chymase-like enzymes and NEP, responsible for generating and metabolizing ET-1(1-31) in rabbit vasculature.
Answers are grounded in this paper and cite their sources.
Preclinical rabbit aorta data on ET-1(1-31) pathways should not alter practice; leaves open chymase-NEP roles in human ET metabolism.
We investigated whether blood vessels contribute to the production of ET-1(1-31) from exogenous big endothelin-1 (BigET-1) in the rabbit and assessed which enzymes are involved in this process. Vascular reactivity experiments, using standard muscle bath procedures, showed that BigET-1 induces contraction in endothelium-intact rabbit aortic rings. Preincubation of the rings with phosphoramidon, CGS35066 or thiorphan reduced BigET-1-induced contraction. Conversely, chymostatin did not affect BigET-1-induced contraction. Thiorphan and phosphoramidon, but not CGS35066 or chymostatin, reduced ET-1(1-31)-induced contraction. None of the enzymatic inhibitors affected the contraction afforded by ET-1.BQ123-, but not BQ788-, selective antagonists for ET(A) and ET(B) receptors, respectively, produced concentration-dependent rightward displacements of the ET-1(1-31) and ET-1 concentration-response curves. By the use of enzymatic assays, we found that the aorta, as well as the heart, lung, kidney and liver, possess a chymase-like activity. Enzyme immunoassays detected significant levels of Ir-ET-1(1-31) in bathing medium of aortas after the addition of BigET-1 (30 nM). Neither thiorphan nor chymostatin altered the levels of Ir-ET-1(1-31). Conversely, the levels of Ir-ET-1(1-31) were increased in the presence of phosphoramidon. This marked increase of the 31-amino-acid peptide was abolished when phosphoramidon and chymostatin were added simultaneously. The major new finding of the present work is that the rabbit aorta generates ET-1(1-31) from exogenously administered BigET-1. Additionally, by measuring the production of ET-1(1-31), we showed that a chymase-like enzyme is involved in this process when ECE and NEP are inhibited by phosphoramidon. Our results also suggest that ET-1(1-31) is an alternate intermediate in the production of ET-1 following BigET-1 administration. Finally, we showed that NEP is the predominant enzymatic pathway involved in the cleavage of ET-1(1-31) to a bioactive metabolite that will act on ET(A) receptors to induce contraction in the rabbit aorta.
No takes yet. Share an insight, caveat, or question.
Tirapelli et al. (2006) studied this question. BigET-1 and enzymatic inhibitors was evaluated on Vascular contraction and generation of ET-1(1-31). The rabbit aorta generates ET-1(1-31) from exogenous BigET-1 via a chymase-like enzyme when ECE and NEP are inhibited, with NEP being the predominant pathway for its cleavage to a bioactive metabolite.
Synapse has enriched 10 related papers. Consider them for comparative context: